Intravitreous CytokinE Level in pAtient With retiNal Detachment

Retinal Detachment Clinical Trial

— ICELAND  

Official title:

Intravitreous CytokinE Level in pAtient With retiNal Detachment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03318588
• Other study ID #: 2017-A02195-48
• Status: Completed
• Start date: November 15, 2017
• Est. completion date: October 11, 2018

Study information

• Verified date: July 2022
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Photoreceptor apoptosis is the basis for permanent visual loss in a number of retinal disorders including age-related macular degeneration (AMD) and retinal detachment (RD). Thus, despite tremendous advances in vitreoretinal surgery and management of rhegmatogenous RD leading to a primary reattachment rate over 95%, some patients show poor visual recovery because of photoreceptor apoptosis.

Physiologically, microglial cells (resident macrophages) are present only in the inner retina. The subretinal space, located between the retinal pigment epithelium (RPE) and the photoreceptor outer segments (POS), is devoid of all mononuclear phagocytes and form a zone of immune privilege. In AMD, several studies showed a strong association between subretinal mononuclear phagocytes infiltration and advanced forms of AMD. Experimental work in mice suggest that this infiltration plays an important role in the pathogenesis of this condition by producing inflammatory cytokines.

RD-induced photoreceptor apoptosis might result from similar mechanisms. The aim of this study is to determine the cytokine profile in vitreous samples from patients with RD and to compare it with those from control patients with macular hole.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: October 11, 2018
• Est. primary completion date: June 28, 2018
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with primary retinal detachment requiring vitrectomy

• Patients with idiopathic macular hole requiring vitrectomy

Exclusion Criteria:

• History of retinal detachment or intraocular inflammatory diseases

Related Conditions & MeSH terms

• Dissociative Disorders
• Retinal Detachment

Intervention

Procedure:
• Vitrectomy
Pars plana vitrectomy

Locations

Country	Name	City	State
France	Brabois Hospital	Vandœuvre-lès-Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intravitreous cytokine levels		up to one month after surgery